Goldman Sachs’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,980,144
| Closed | -$79.7M | – | 6553 |
|
|
2026
Q1 | $79.7M | Buy |
1,980,144
+1,790,939
| +947% | +$38.6M | 0.01% | 1201 |
|
|
2025
Q4 | $4.75M | Buy |
189,205
+64,832
| +52% | +$1.52M | ﹤0.01% | 3792 |
|
|
2025
Q3 | $2.81M | Sell |
124,373
-91,626
| -42% | -$2.14M | ﹤0.01% | 4173 |
|
|
2025
Q2 | $3.74M | Sell |
215,999
-91,710
| -30% | -$1.7M | ﹤0.01% | 3684 |
|
|
2025
Q1 | $6.73M | Buy |
307,709
+64,742
| +27% | +$1.79M | ﹤0.01% | 3062 |
|
|
2024
Q4 | $7.75M | Buy |
242,967
+47,901
| +25% | +$1.44M | ﹤0.01% | 3034 |
|
|
2024
Q3 | $5.63M | Buy |
195,066
+48,140
| +33% | +$1.78M | ﹤0.01% | 3240 |
|
|
2024
Q2 | $5.64M | Sell |
146,926
-172,550
| -54% | -$7.81M | ﹤0.01% | 3041 |
|
|
2024
Q1 | $18.8M | Buy |
319,476
+8,893
| +3% | +$567K | ﹤0.01% | 1896 |
|
|
2023
Q4 | $18.6M | Sell |
310,583
-21,210
| -6% | -$1.08M | ﹤0.01% | 1969 |
|
|
2023
Q3 | $12.6M | Sell |
331,793
-303,104
| -48% | -$13.3M | ﹤0.01% | 2195 |
|
|
2023
Q2 | $57.8M | Sell |
634,897
-28,298
| -4% | -$2.44M | 0.01% | 995 |
|
|
2023
Q1 | $43.7M | Sell |
663,195
-398,508
| -38% | -$23M | 0.01% | 1158 |
|
|
2022
Q4 | $54.9M | Buy |
1,061,703
+104,025
| +11% | +$5.52M | 0.01% | 1102 |
|
|
2022
Q3 | $65.4M | Buy |
957,678
+147,279
| +18% | +$8.72M | 0.02% | 930 |
|
|
2022
Q2 | $36.6M | Buy |
810,399
+310,145
| +62% | +$14.1M | 0.01% | 1369 |
|
|
2022
Q1 | $25.4M | Buy |
500,254
+2,172
| +0.4% | +$95.9K | 0.01% | 1852 |
|
|
2021
Q4 | $23.5M | Sell |
498,082
-525,088
| -51% | -$20.7M | ﹤0.01% | 1970 |
|
|
2021
Q3 | $33.7M | Buy |
1,023,170
+329,130
| +47% | +$18.5M | 0.01% | 1592 |
|
|
2021
Q2 | $43.9M | Sell |
694,040
-429,701
| -38% | -$22.2M | 0.01% | 1377 |
|
|
2021
Q1 | $48.2M | Buy |
1,123,741
+34,210
| +3% | +$1.62M | 0.01% | 1192 |
|
|
2020
Q4 | $62.3M | Sell |
1,089,531
-242,079
| -18% | -$10.2M | 0.02% | 952 |
|
|
2020
Q3 | $40.2M | Buy |
1,331,610
+318,550
| +31% | +$9.52M | 0.01% | 1165 |
|
|
2020
Q2 | $33.1M | Buy |
1,013,060
+378,343
| +60% | +$12.2M | 0.01% | 1285 |
|
|
2020
Q1 | $17M | Buy |
634,717
+168,482
| +36% | +$5.98M | 0.01% | 1637 |
|
|
2019
Q4 | $14.3M | Buy |
466,235
+101,602
| +28% | +$2.81M | ﹤0.01% | 2147 |
|
|
2019
Q3 | $8.78M | Sell |
364,633
-56,223
| -13% | -$1.55M | ﹤0.01% | 2423 |
|
|
2019
Q2 | $10.7M | Buy |
420,856
+223,238
| +113% | +$4.54M | ﹤0.01% | 2311 |
|
|
2019
Q1 | $3.85M | Buy |
197,618
+139,510
| +240% | +$2.19M | ﹤0.01% | 3191 |
|
|
2018
Q4 | $767K | Sell |
58,108
-14,892
| -20% | -$228K | ﹤0.01% | 4126 |
|
|
2018
Q3 | $1.3M | Buy |
73,000
+8,330
| +13% | +$154K | ﹤0.01% | 3887 |
|
|
2018
Q2 | $1.42M | Buy |
+64,670
| New | +$1.49M | ﹤0.01% | 3845 |
|
Other funds holding APLS
Goldman Sachs's APLS Position: Q2 2026 in Review
Goldman Sachs sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,980,144 shares — an estimated $79.7M sold.
Goldman Sachs first reported a position in APLS in Q2 2018 and held it in 32 quarters. The position peaked at $79.7M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Goldman Sachs reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Goldman Sachs sold 1,980,144 Apellis Pharmaceuticals shares in Q2 2026, an estimated $79.7M.
- Goldman Sachs first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 32 quarters.
- Goldman Sachs's Apellis Pharmaceuticals position peaked at $79.7M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.